Thomas J. Campbell, Jr. Image

Thomas J. Campbell, Jr.


Neal Gerber Eisenberg

Thomas J. Campbell, Jr. is a Partner with Neal Gerber Eisenberg. Tom represents clients in patent and trademark prosecution, intellectual property litigation, and post-grant patent challenges before the Patent Trial and Appeal Board (PTAB). Tom has a broad base of experience in various technological and business areas, particularly in pharmaceutical, biotechnology, chemical and medical device inventions. He drafts invalidity opinions, investigates freedom to operate, counsels on strategic portfolio management, and conducts due diligence investigations prior to acquisition or merger.

He has extensive scientific research experience in both industry and academic settings. Tom worked as a pharmacologist in the Advanced Technology Division of Abbott Laboratories to identify safe and efficacious drug candidates. His skill as a researcher was recognized when Abbott honored him with its Global Pharmaceutical Research and Development Award for Leadership. Tom also conducted various chemical and biological research both at the University of Notre Dame and University of Chicago. His chemical research was directed toward organometallic catalysis. His biological research involved investigating the underlying causes of diabetes — including the molecular biology of ion channels and the role genetics plays in beta cell dysfunction.  This experience as a scientist enables Tom to effectively communicate with clients and inventors seeking patent protection or counseling.

Tom has published peer-reviewed scientific journal articles, including multiple articles in the Journal of Medicinal Chemistry and the Journal of Cardiovascular Pharmacology. Tom has been published in the National Law Journal and coauthored book chapters in the American Bar Association’s publications ANDA Litigation and Pre-ANDA Litigation.  He is also often sought out for commentary and counseling on emerging trends and proposed rules relating to PTAB trials.

He has represented pro bono clients through the DePaul Technology/Intellectual Property Clinic, Equip for Equality and Lawyers for the Creative Arts. He is also a trained mediator and has been certified by the Center for Conflict Resolution in Chicago.

Tom has been listed in the 2016-2020 editions of Illinois Super Lawyers as a Rising Star and the 2021 edition of Best Lawyers in America for his expertise in Patent Law.

Recent Articles by Thomas J. Campbell, Jr.

SCOTUS Takes on Scope of Enablement Inquiry in Amgen v. Sanofi: Implications for Pharma/ Biotech and Beyond

On November 4, the U.S. Supreme Court granted Amgen’s petition for certiorari against the advice of the U.S. government – taking up Amgen’s challenge to the Federal Circuit’s enablement review of its PCSK9 antibody patents covering evolocumab (Repatha®). In its petition, Amgen asserts that the Federal Circuit has gone too far in invalidating its PCSK9 antibody patents by imposing a disclosure burden beyond the requirements of 35 U.S.C. § 112. Notably, the Supreme Court, albeit with a different composition, recently declined to hear several other similar cases raising issues with the Federal Circuit’s enablement precedent.